Biotech, small-cap, long/short equity, special situations
Exact Sciences Is A Near-Term Short Due To Risks And Assumptions About Its Future Business
The market need for Cologuard
Only 0.3% of the population currently suffers from colon cancer, but the lifetime risk is higher at 5%, which benefits the colon cancer screening market. According to the American Cancer Society: "96,830 new cases ...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
Access Top Ideas, chosen by Seeking Alpha’s editors
Filter long and short ideas by market cap and sector
Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.